SLC25A3 Antibody

What is SLC25A3 and why is it significant in mitochondrial research?

SLC25A3, also known as phosphate transport protein (PTP), is a critical mitochondrial phosphate carrier protein that facilitates phosphate transport into the mitochondrial matrix - an essential process for ATP synthesis and cellular energy metabolism. This 40.1 kDa (calculated) multi-pass inner mitochondrial membrane protein consists of 362 amino acids and exists in two alternatively spliced isoforms (A and B) .

SLC25A3 is highly expressed in tissues with high energy demands such as pancreas, skeletal muscle, and heart. The gene is located on human chromosome 12q23.1, and defects are associated with mitochondrial phosphate carrier deficiency (MPCD) . Recent research has found that SLC25A3 also interacts with NLRP3 and negatively regulates inflammasome activation, suggesting its broader role beyond energy metabolism .

What applications are validated for SLC25A3 antibodies?

SLC25A3 antibodies have been validated for multiple applications:

For optimal results, each antibody should be titrated in specific testing systems .

How should SLC25A3 antibodies be stored for maximum stability?

Most SLC25A3 antibodies should be stored at -20°C and are typically stable for one year after shipment. Many suppliers provide them in storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Some specialized antibody formats, like conjugation-ready formats without BSA and azide, should be stored at -80°C .

Aliquoting is generally unnecessary for -20°C storage for glycerol-containing formulations. Some preparations contain 0.1% BSA in small volume (20μl) formats . Always refer to the manufacturer's specific storage recommendations as they may vary based on antibody formulation.

What considerations are important when selecting between monoclonal and polyclonal SLC25A3 antibodies?

The choice between monoclonal and polyclonal SLC25A3 antibodies should be guided by your specific research application:

Monoclonal SLC25A3 antibodies:

• Provide consistent lot-to-lot reproducibility with single epitope specificity

• Ideal for quantitative applications like cytometric bead arrays

• Examples include mouse monoclonal antibodies like the F-1 clone that detects SLC25A3 protein from mouse, rat, and human origins

• Best for applications requiring high specificity like protein interaction studies

Polyclonal SLC25A3 antibodies:

• Recognize multiple epitopes, potentially providing stronger signal in applications like Western blotting

• Most commonly raised in rabbits against recombinant SLC25A3 protein

• Useful when protein conformation may vary across experimental conditions

• Example: Rabbit polyclonal antibodies purified by antigen affinity that detect human and mouse SLC25A3

When investigating SLC25A3's interaction with NLRP3 or studying its role in inflammasome regulation, monoclonal antibodies may provide more consistent results for co-immunoprecipitation experiments .

What is the optimal Western blot protocol for detecting SLC25A3?

For optimal Western blot detection of SLC25A3:

• Sample preparation:

  • Use tissues with known high SLC25A3 expression (heart, pancreas, skeletal muscle)

  • For cell lines, MCF-7 has been validated for SLC25A3 detection

  • Include mitochondrial enrichment steps for enhanced sensitivity

• Gel and transfer conditions:

  • Use 10-12% SDS-PAGE gels

  • Transfer to PVDF membrane at 100V for 1 hour or 30V overnight

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary SLC25A3 antibody at dilution 1:500-1:1000 overnight at 4°C

  • Wash 3x with TBST

  • Incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

  • Wash 3x with TBST

• Detection:

  • Develop using ECL reagent

  • Expected molecular weight: 30-40 kDa (observed molecular weight may vary from the calculated 40.1 kDa)

• Controls:

  • Positive control: Mouse pancreas tissue or MCF-7 cells

  • Negative control: Tissues with SLC25A3 knockdown or antibody neutralized with blocking peptide

How can researchers validate SLC25A3 antibody specificity for their experimental systems?

To validate SLC25A3 antibody specificity:

• Knockout/knockdown validation:

  • Use SLC25A3 knockdown models such as those described in the literature where Slc25a3 deletion was induced in 8-week-old mice by tamoxifen injections

  • Compare Western blot signal between wildtype and knockout/knockdown samples

  • A true specific antibody will show significantly reduced signal in knockout/knockdown samples

• Blocking peptide validation:

  • Pre-incubate the antibody with its specific neutralizing peptide (e.g., SLC25A3 (F-1) Neutralizing Peptide)

  • Run parallel Western blots with blocked and unblocked antibody

  • Signal should be abolished or significantly reduced with the blocked antibody

• Multiple antibody validation:

  • Test multiple antibodies targeting different epitopes of SLC25A3

  • Consistent patterns across antibodies increase confidence in specificity

• Cross-reactivity testing:

  • Test the antibody against samples from multiple species if working in animal models

  • Confirm reactivity with human, mouse, or rat samples as indicated in product specifications

How can researchers use SLC25A3 antibodies to investigate the protein's interaction with NLRP3 inflammasome components?

Recent research has revealed that SLC25A3 interacts with and negatively regulates NLRP3 inflammasome activation . To investigate this interaction:

• Co-immunoprecipitation (Co-IP):

  • Perform reciprocal Co-IP experiments using both anti-SLC25A3 and anti-NLRP3 antibodies

  • Use appropriate lysis buffers that preserve membrane protein interactions

  • Include mitochondrial fractionation to enrich for the interaction compartment

  • Follow validated protocols showing that NLRP3 could interact with SLC25A3 in HEK293T cells

• Subcellular localization studies:

  • Use immunofluorescence with anti-SLC25A3 and anti-NLRP3 antibodies

  • Include mitochondrial markers (e.g., MitoTracker)

  • Analyze colocalization before and after inflammasome activation

  • Research has shown that interaction of NLRP3 and SLC25A3 is significantly enhanced in mitochondria during inflammasome activation

• Domain mapping:

  • Use glutathione-S-transferase pull-down assays to confirm direct interaction

  • Focus on nucleotide-binding domain and leucine-rich repeat domains of NLRP3, which have been shown to interact with SLC25A3

  • Design appropriate controls to demonstrate specificity

• Functional validation:

  • Conduct ubiquitination assays to assess if SLC25A3 affects NLRP3 ubiquitination

  • Measure inflammasome activation (IL-1β secretion, caspase-1 activation) in SLC25A3 overexpression and knockdown conditions

What methodological approaches are most effective for studying SLC25A3's role in mitochondrial dysfunction models?

To investigate SLC25A3's role in mitochondrial dysfunction:

• Genetic manipulation models:

  • Use Slc25a3 fl/flxMCM mice where SLC25A3 deletion can be induced with tamoxifen (25 mg/kg for 5 consecutive days)

  • Develop cell models with CRISPR/Cas9-mediated knockdown or overexpression of SLC25A3

  • Use these models to assess direct impact on mitochondrial function

• Mitochondrial function assays:

  • Oxygen consumption rate (OCR) measurements

  • ATP synthesis assays

  • Mitochondrial membrane potential assessment

  • ROS production measurement

  • Calcium handling studies

• Proteomic and acylome analyses:

  • Research has shown that SLC25A3 deletion induces significant acylome remodeling

  • Use targeted proteomics approaches to identify changes in mitochondrial protein expression and post-translational modifications

  • Apply advanced mass spectrometry techniques to detect acetylation changes in SLC25A3-deficient models

• Tissue-specific analyses:

  • Focus on tissues with high energy demands like heart, where SLC25A3 deletion causes mitochondrial cardiomyopathy

  • Compare phenotypes between different tissues to understand tissue-specific roles

  • Correlate findings with human mitochondrial phosphate carrier deficiency (MPCD) manifestations

How can researchers effectively distinguish between SLC25A3 isoforms in experimental systems?

SLC25A3 exists in two alternatively spliced isoforms (A and B). Distinguishing between these isoforms requires specialized approaches:

• Isoform-specific antibodies:

  • Select antibodies raised against unique regions of each isoform

  • Validate specificity using recombinant proteins of each isoform

  • If isoform-specific antibodies are unavailable, consider developing custom antibodies against unique peptide sequences

• RT-PCR and qPCR:

  • Design primers spanning the alternatively spliced regions

  • Optimize PCR conditions to differentiate between isoform transcripts

  • Use sequencing to confirm isoform identity

  • Quantify relative expression of each isoform across tissues or conditions

• Protein separation techniques:

  • Use high-resolution SDS-PAGE or 2D gel electrophoresis to separate isoforms based on subtle size differences

  • Employ Phos-tag gels if phosphorylation differences exist between isoforms

  • Confirm identity through mass spectrometry with isoform-specific peptide detection

• Functional characterization:

  • Express each isoform individually in knockout backgrounds

  • Compare functional parameters such as phosphate transport efficiency

  • Analyze isoform-specific protein interactions using targeted proteomics

What strategies can researchers employ to investigate post-translational modifications of SLC25A3 and their impact on protein function?

Investigating post-translational modifications (PTMs) of SLC25A3:

• PTM-specific enrichment:

  • Use phospho-enrichment techniques (TiO2, IMAC) to study SLC25A3 phosphorylation

  • Apply acetyl-lysine antibody pulldown to assess acetylation

  • Employ ubiquitin enrichment strategies to study ubiquitination patterns

  • Research has shown that SLC25A3 interaction with NLRP3 promotes ubiquitination of NLRP3

• Mass spectrometry approaches:

  • Use targeted MS/MS to identify specific modification sites

  • Apply parallel reaction monitoring (PRM) for quantitative assessment

  • Compare PTM profiles between normal and disease states or experimental conditions

  • Correlate with SLC25A3 deletion-induced acetylome remodeling findings

• Site-directed mutagenesis:

  • Generate mutants of potential modification sites (e.g., K to R for acetylation sites)

  • Express in appropriate cellular systems

  • Assess impact on:

    • Protein localization

    • Protein stability

    • Interaction with NLRP3 and other partners

    • Phosphate transport function

• Functional correlation:

  • Correlate PTM changes with mitochondrial function parameters

  • Investigate how modifications affect SLC25A3's role in inflammasome regulation

  • Study modification changes during cellular stress conditions

What experimental design considerations are critical when using SLC25A3 antibodies to study protein-protein interactions in the inflammasome pathway?

When studying SLC25A3's role in the inflammasome pathway:

• Stimulation protocols:

  • Include appropriate inflammasome activators (e.g., ATP, nigericin)

  • Use time course experiments to capture dynamic interactions

  • Consider priming steps with LPS or other TLR agonists

  • Research shows interaction between NLRP3 and SLC25A3 is enhanced during inflammasome activation

• Cell and tissue selection:

  • Use relevant cell types like THP-1-derived macrophages and bone marrow-derived macrophages (BMDMs)

  • Include both immortalized cell lines and primary cells

  • Consider tissue-specific differences in inflammasome regulation

• Interaction specificity controls:

  • Include negative controls (e.g., ASC, caspase-1) that have been shown not to interact with SLC25A3

  • Use domain deletion mutants to map interaction interfaces

  • Apply proximity ligation assays to confirm interactions in intact cells

• Mechanistic validation:

  • Assess how SLC25A3 affects established NLRP3 interaction partners like NEK7

  • Measure functional outcomes (IL-1β release, pyroptosis)

  • Correlate interaction strength with functional consequences

  • Test how mitochondrial dysfunction affects the SLC25A3-NLRP3 interaction